Exenatide Plus Dapagliflozin Significantly Reduces A1C Compared to Either Drug Alone: DURATION-8 Results

December, 2016
December 2016. This randomized controlled trial examined the effect on A1C of exenatide plus dapagliflozin compared with either drug alone. Over 28 weeks, among patients with type 2 diabetes, exenatide plus dapagliflozin reduced A1C by 2.0%. This was significant versus a reduction of 1.6% in the exenatide group (95% confidence interval [CI], −0.6 to −0.1; P=0.004), and compared to a reduction of 1.4% in the dapagliflozin group (95% CI, –0.8 to −0.3; P